Jodi Lipof, M.D.
Assistant Professor - Department of Medicine, Hematology/Oncology (SMD)
Residency & Fellowship
Fellowship, Hematology & Oncology, University of Rochester Medical Center. 2018 - 2021
Residency, Internal Medicine, University of Rochester Medical Center. 2016 - 2018
Internship, Internal Medicine, University of Rochester Medical Center. 2015 - 2016
MD | George Washington University Hospital (USA). 2015
Lead Researcher: Jodi Lipof
Selinexor is a drug that has been approved in the treatment of patients with symptomatic multiple myeloma. The standard of care for patients with Smoldering Multiple Myeloma remains observation, but there are numerous clinical trials investigating in...
Lipof JJ, Huselton EJ, Zent CS, Evans A, Zhang B, Rothberg PG, Bennett JM
Case reports in hematology.. 2021 2021 :5574766. Epub 07/03/2021.
Lipof JJ, Barr PM
Hematology/oncology clinics of North America.. 2020 August 34 (4):757-769. Epub 05/05/2020.
Lipof JJ, Loh KP, O'Dwyer K, Liesveld JL
Cancers.. 2018 June 410 (6)Epub 06/04/2018.
Ram J, Flamm G, Balys M, Sivagnanalingam U, Rothberg PG, Iqbal A, Myers JR, Corbett A, Ashton JM, Mendler JH
Blood advances.. 2017 March 141 (8):500-503. Epub 03/14/2017.
Breast and cervical cancer screening behaviors of African American sexual minority women.
Matthews AK, Li CC, Ross N, Ram JJ, Ramsey R, Aranda F.
J Gen Pract. 2013; 107(2).